At 6.2% CAGR, Europe Clinical Reference Laboratory Market is Projected to be Worth US$ 21,670.00 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Europe clinical reference laboratory market was valued at US$ 13,431.17 million in 2023 and is expected to reach US$ 21,670.00 million by 2031, registering a CAGR of 6.2% from 2023 to 2031. Strategic initiatives with reference laboratories and increasing number of clinical trials are among the critical factors attributed to drive the Europe clinical reference laboratory market growth.

Strategic initiatives by the laboratory service providers such as acquisition, alliance, and expansion with reference labs are among the most cost-effective ways to obtain the benefits of better patient care and cost efficiency. In 2024, Sweden and Denmark formed a public health partnership to build an EU reference laboratory (EURL) for antimicrobial resistance (AMR). The EURL will aid in infection preparedness and diagnostics. The European Commission (EC) has designated six EURLs for public health, including AMR, with the goal of bolstering EU defenses against significant cross-border threats. In 2024, the European Commission designated RIVM as the current EURL for vector-borne viral pathogens.

On the contrary, complications related to regulatory framework and adoption of continuous technological developments hamper the growth of Europe clinical reference laboratory market.

Based on service provider, the Europe clinical reference laboratory market is segmented into hospital-based, standalone, and clinic-based. The hospital-based segment held 60.4% market share in 2023, amassing US$ 8,117.25 million. It is projected to garner US$ 12,925.65 million by 2031 to register 6.1% CAGR during 2023-2031.

In terms of application, the Europe clinical reference laboratory medicine market is categorized into laboratory medicine, clinical trials, and others. The laboratory medicine segment held 71.6% share of Europe clinical reference laboratory market in 2023, amassing US$ 9,616.34 million. It is anticipated to garner US$ 15,186.79 million by 2031 to expand at 5.9% CAGR during 2023-2031.

By country, the Europe clinical reference laboratory market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 26.5% share of Europe clinical reference laboratory market in 2023. It was assessed at US$ 3,559.45 million in 2023 and is likely to hit US$ 5,820.81 million by 2031, registering a CAGR of 6.3% during 2023-2031.

Key players operating in the Europe clinical reference laboratory market are Sonic Healthcare Ltd, UNILABS, Laboratory Corp of America Holdings, Quest Diagnostics Inc, SYNLAB International GmbH, and Myraid Genetics Inc, among others.

• In September 2020, Unilabs, the leading European diagnostic services provider, has completed the acquisition of Saltro, one of the largest and most innovative diagnostics companies in the Netherlands. The acquisition significantly expands Unilabs' presence in the Netherlands, where its Medlon team currently provides laboratory diagnostics services in the eastern part of the country. With the addition of Saltro, Unilabs become one of the Netherlands' largest and most complete diagnostics providers.
  
  
• In April 2024, SYNLAB launched myEDIT-B is the first clinically validated test for the differential diagnosis between bipolar disorder and unipolar depression, signalling a paradigm shift in the identification of this mental health disorder and thus increasing the effectiveness of the treatment approach.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com